 Cat allergy is an increasingly prevalent condition, affecting 10-15 of patients with allergic rhinoconjunctivitis andor asthma. Cat-PAD is a novel, synthetic, allergen-derived peptide desensitising vaccine, currently being developed for the treatment of cat allergy. 